Silo Pharma Stock Performance

SILO Stock  USD 0.33  0.02  5.71%   
The entity has a beta of 2.03, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Silo Pharma will likely underperform. At this point, Silo Pharma has a negative expected return of -0.6%. Please make sure to validate Silo Pharma's total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Silo Pharma performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Silo Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in March 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
  

Silo Pharma Relative Risk vs. Return Landscape

If you would invest  51.00  in Silo Pharma on November 5, 2025 and sell it today you would lose (18.00) from holding Silo Pharma or give up 35.29% of portfolio value over 90 days. Silo Pharma is currently does not generate positive expected returns and assumes 4.8869% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of otc stocks are less volatile than Silo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Silo Pharma is expected to under-perform the market. In addition to that, the company is 6.44 times more volatile than its market benchmark. It trades about -0.12 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.1 per unit of volatility.

Silo Pharma Target Price Odds to finish over Current Price

The tendency of Silo OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.33 90 days 0.33 
under 95
Based on a normal probability distribution, the odds of Silo Pharma to move above the current price in 90 days from now is under 95 (This Silo Pharma probability density function shows the probability of Silo OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the otc stock has the beta coefficient of 2.03 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Silo Pharma will likely underperform. Additionally Silo Pharma has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Silo Pharma Price Density   
       Price  

Predictive Modules for Silo Pharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Silo Pharma. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.020.335.19
Details
Intrinsic
Valuation
LowRealHigh
0.020.325.18
Details
Naive
Forecast
LowNextHigh
0.010.295.15
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.320.360.41
Details

Silo Pharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Silo Pharma is not an exception. The market had few large corrections towards the Silo Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Silo Pharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Silo Pharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.76
β
Beta against Dow Jones2.03
σ
Overall volatility
0.06
Ir
Information ratio -0.15

Silo Pharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Silo Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Silo Pharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Silo Pharma generated a negative expected return over the last 90 days
Silo Pharma has some characteristics of a very speculative penny stock
Silo Pharma has high historical volatility and very poor performance
Silo Pharma has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 72.1 K. Net Loss for the year was (3.63 M) with profit before overhead, payroll, taxes, and interest of 66.26 K.
Silo Pharma currently holds about 8.85 M in cash with (3.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Silo Pharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Silo OTC Stock often depends not only on the future outlook of the current and potential Silo Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Silo Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding3.1 M
Cash And Short Term Investments7.7 M

Silo Pharma Fundamentals Growth

Silo OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Silo Pharma, and Silo Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Silo OTC Stock performance.

About Silo Pharma Performance

By examining Silo Pharma's fundamental ratios, stakeholders can obtain critical insights into Silo Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Silo Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Inc., a developmental stage biopharmaceutical company, focuses on merging traditional therapeutics with psychedelic research. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey. Silo Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.

Things to note about Silo Pharma performance evaluation

Checking the ongoing alerts about Silo Pharma for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Silo Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Silo Pharma generated a negative expected return over the last 90 days
Silo Pharma has some characteristics of a very speculative penny stock
Silo Pharma has high historical volatility and very poor performance
Silo Pharma has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 72.1 K. Net Loss for the year was (3.63 M) with profit before overhead, payroll, taxes, and interest of 66.26 K.
Silo Pharma currently holds about 8.85 M in cash with (3.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evaluating Silo Pharma's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Silo Pharma's otc stock performance include:
  • Analyzing Silo Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Silo Pharma's stock is overvalued or undervalued compared to its peers.
  • Examining Silo Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Silo Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Silo Pharma's management team can help you assess the OTC Stock's leadership.
  • Pay attention to analyst opinions and ratings of Silo Pharma's otc stock. These opinions can provide insight into Silo Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Silo Pharma's otc stock performance is not an exact science, and many factors can impact Silo Pharma's otc stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Other Information on Investing in Silo OTC Stock

Silo Pharma financial ratios help investors to determine whether Silo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Silo with respect to the benefits of owning Silo Pharma security.